Guggenheim analyst Yatin Suneja downgrades Relmada Therapeutics (NASDAQ:RLMD) from Buy to Neutral.
Guggenheim Downgrades Relmada Therapeutics to Neutral
Guggenheim analyst Yatin Suneja downgrades Relmada Therapeutics (NASDAQ:RLMD) from Buy to Neutral.
Related Posts
5 Analysts Have This to Say About Cooper Companies
Within the last quarter, Cooper Companies (NYSE:COO) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Harvest One Announces Effective Date Of Name Change To Delivra Health Brands
TSX Venture Exchange has conditionally approved the name change of Harvest One Cannabis Inc. (OTCQB: HRVOF) (TSXV:HVT) to "Delivra Health Brands Inc.".